Masimo announced FDA clearance and full market release of Rad-97™ Pulse CO-Oximeter®, including configurations with blood pressure and capnography.
NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of Eve™, a critical congenital heart disease (CCHD) newborn screening application, for the Rad-97™ Pulse ...
Masimo said it received a subpoena from the Department of Justice seeking documents and information related to its Rad-G and Rad-97 pulse oximeters, including complaints about the products and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback